Next-generation Biacore 8™ series SPR systems
The Biacore™ 8S and Biacore™ 8S+ SPR systems deliver one automated platform for smarter screening and deeper binding characterization across all therapeutic modalities. Designed to flex seamlessly between rapid, high‑throughput screening and high‑precision kinetic analysis, these systems enable confident decision‑making throughout drug discovery and development.
At the core of the platform is a parallel eight‑channel configuration with up to 16 flow cells, combined with multiple microplate capacity. This architecture allows researchers to move efficiently from early‑stage candidate ranking to detailed interaction analysis without changing systems or workflows.
Speed to results is a defining advantage. The system supports rapid screening and quantification, enabling analysis of up to 384 proteins in just 15 minutes and estimation of protein concentration for 384 crude samples in 24 minutes. During off‑rate ranking, efficient use of target material can reduce consumption by up to 50% without compromising data quality. For full kinetic characterisation, accurate rate constants can be generated for 48 samples in under 2.5 hours, covering both fast and slow interactions.
Scalable and flexible workflows support growing throughput demands. An eight‑needle setup with 8 or 16 flow cells enables parallel processing, while integrated liquid and plate handling accommodates up to twelve 96‑ or 384‑well plates. True walk‑away operation allows runs to be stacked for up to 72 hours unattended, maximising insight while saving time and resources.
High sensitivity ensures data confidence, even for challenging interactions. The system supports confident analysis of fragments and small molecules with no lower molecular weight limit and detection down to 1 pM. A flow‑based design delivers stable, reliable measurements across a wide range of on‑ and off‑rates while minimising mass transport effects and rebinding, resulting in cleaner, high‑resolution kinetic data.
Together, Biacore™ 8S and 8S+ systems provide a single, automated SPR solution that combines speed, scalability, and sensitivity—supporting faster screening, deeper characterisation, and more confident progression of drug candidates.
At the core of the platform is a parallel eight‑channel configuration with up to 16 flow cells, combined with multiple microplate capacity. This architecture allows researchers to move efficiently from early‑stage candidate ranking to detailed interaction analysis without changing systems or workflows.
Speed to results is a defining advantage. The system supports rapid screening and quantification, enabling analysis of up to 384 proteins in just 15 minutes and estimation of protein concentration for 384 crude samples in 24 minutes. During off‑rate ranking, efficient use of target material can reduce consumption by up to 50% without compromising data quality. For full kinetic characterisation, accurate rate constants can be generated for 48 samples in under 2.5 hours, covering both fast and slow interactions.
Scalable and flexible workflows support growing throughput demands. An eight‑needle setup with 8 or 16 flow cells enables parallel processing, while integrated liquid and plate handling accommodates up to twelve 96‑ or 384‑well plates. True walk‑away operation allows runs to be stacked for up to 72 hours unattended, maximising insight while saving time and resources.
High sensitivity ensures data confidence, even for challenging interactions. The system supports confident analysis of fragments and small molecules with no lower molecular weight limit and detection down to 1 pM. A flow‑based design delivers stable, reliable measurements across a wide range of on‑ and off‑rates while minimising mass transport effects and rebinding, resulting in cleaner, high‑resolution kinetic data.
Together, Biacore™ 8S and 8S+ systems provide a single, automated SPR solution that combines speed, scalability, and sensitivity—supporting faster screening, deeper characterisation, and more confident progression of drug candidates.